Lack of detrimental or therapeutic effects of cyclooxygenase inhibition in bile duct-ligated rats with hepatic encephalopathy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 9, 2006, Pages 1483-1487

  Chan, Cho Yu ^a,c   Lee, Fa Yauh ^a,c   Wang, Teh Fang ^b   Huang, Seng Wong ^c   Chang, Full Young ^a,c   Lu, Rei Hwa ^a   Chen, Yi Chou ^a   Wang, Sun Sang ^a,c   Huang, Hui Chun ^a,c   Lee, Shou Dong ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Armed Forces Sung Shan Hospital   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cyclooxygenase; Hepatic encephalopathy; Indomethacin; Motor activities; Prostacyclin; Tumor necrosis factor ; Vasodilatation

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; INDOMETACIN; LIVER ENZYME; PROSTAGLANDIN SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT LIGATION; BILIARY CIRRHOSIS; BRAIN BLOOD FLOW; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INHIBITION; HEPATIC ENCEPHALOPATHY; MALE; MOTOR ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN;

EID: 33746617881     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04261.x     Document Type: Article

References (37)

1. Gammal SH, Hones EA. Hepatic encephalopathy. Med. Clin. North Am. 1989; 73: 793-813.
2. Sherlock S. Fulminant hepatic failure. Adv. Intern. Med. 1993; 38: 245-67.
3. Mousseau DD, Butter Worth RF. Current theories on the pathogenesis of hepatic encephalopathy. Soc. Exp. Biol. Med. 1994; 206: 329-44.
4. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-63.
5. Pizcueta P, Piqué JM, Fernandéz M et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992; 103: 1909-15.
6. ω-nitro-L- arginine administration corrects peripheral vasodilation and systemic capillary hypotension, and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993; 17: 84-90.
7. Sitzmann JV, Bulkley GB, Mitchell MC, Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann. Surg. 1989; 209: 322-7.
8. Bruix J, Bosch J, Kravetz D, Mastai R, Rodez J. Effects of prostacyclin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88: 430-5.
9. Chu CJ, Wang SS, Lee FY et al. Detrimental effects of nitric oxide inhibition on hepatic encephalopathy in rats with thioacetamide-induced fulminant hepatic failure. Eur. J. Clin. Invest. 2001; 31: 156-63.
10. Chu CJ, Hsiao CC, Wang TF et al. Prostacyclin inhibition by indomethacin aggravates hepatic damage and encephalopathy in rats with thioacetamide-induced fulminant hepatic failure. World J. Gastroenterol. 2005; 11: 232-6.
11. Klin MJ, Waluga M, Madej A, Plewka A, Herman ZS. Hypothalamic, striatal and plasma leucine enkephalin level in two rat models of portal hypertension. Pol. J. Pharmacol. 1993; 45: 281-90.
12. Minuk GY, Sarjeant EJ. The effect of (a) neomycin and lactulose treatment on systemic and portal serum GABA levels in rats and (b) pH changes on [3H] GABA binding to isolated rat hepatocytes. Clin. Invest. Med. 1988; 11: 373-6.
13. Chan CY, Huang SW, Wang TF et al. Lack of detrimental effects of nitric oxide inhibition in bile duct-ligated rats with hepatic encephalopathy. Eur. J. Clin. Invest. 2004; 34: 122-8.
14. Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct ligation obstruction: a new experimental model of cirrhosis in the rat. Br. J. Exp. Pathol. 1984; 65: 305-11.
15. Lebrec D, Blanchet L. Effect of two models of portal hypertension on splanchnic organ blood flow in the rat. Clin. Sci. 1985; 68: 23-8.
16. Fernandez M, Pizcueta P, Garcia-Pagan JC et al. Effects of ritanserin, a selective and specific S2-serotoninergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long-term bile duct ligation. Hepatology 1993; 18: 389-93.
17. Castaneda B, Debernardi-Venon W, Bandi JC et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000; 31: 581-6.
18. A-benzodiazepine receptor on hepatic encephalopathy in the rat: comparison with uremic encephalopathy. Hepatology 1991; 14: 963-8.
19. Bengtsson F, Gage FH, Jeppsson B, Nobin A, Rosengren E. Brain monoamine metabolism and behavior in portocaval shunted rats. Exp. Neurol. 1985; 90: 21-35.
20. Koyama K, Muto I, Yamauchi H, Takagi Y, Anezaki T. Biochemical study of fibrosis in the rat liver in biliary obstruction. Tohoku J. Exp. Med. 1975; 116: 161-72.
21. Chu CJ, Lee FY, Wang SS et al. Establishment of an animal model of hepatic encephalopathy. J. Chin. Med. Assoc. 2000; 63: 263-9.
22. Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J. Hepatol. 1999; 31: 771-6.
23. Haussinger D, Kircheis G, Fischer R, Schliess F, von Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocytes swelling and low-grade cerebral edema. J. Hepatol. 2000; 32: 1035-8.
24. Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab. Brain Dis. 2002; 17: 221-7.
25. Vaquero J, Chung C, Cahill ME, Blei AT. Pathogenesis of hepatic encephalopathy in acute liver failure. Semin. Liver Dis. 2003; 23: 259-69.
26. Lockwood AH, Yap EWH, Wong W. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J. Cereb. Blood Flow Metab. 1991; 11: 337-41.
27. Janigro D, West GA, Nguyen TS, Winn HR. Regulation of blood-brain barrier endothelial cells by nitric oxide. Circ. Res. 1994; 75: 528-38.
28. 2 formation parallels blood-brain barrier disruption in an experimental rat model of bacterial meningitis. Brain Res. Bull. 1998; 46: 541-6.
29. Harrigan MR, Tuteja S, Neudeck BL. Indomethacin in the management of elevated intracranial pressure: a review. J. Neurotrauma 1997; 14: 637-50.
30. Chung C, Gottstein J, Blei AT. Indomethacin prevents the development of experimental ammonia-induced brain edema in rats after portocaval anastomosis. Hepatology 2001; 34: 249-54.
31. Stachura J, Tarnawski A, Ivey KJ et al. Prostaglandin protection of carbon tetrachloride-induced liver cell necrosis in the rat. Gastroenterology 1981; 81: 211-17.
32. Guarner F, Boughton-Smith NK, Blackwell GJ, Moncada S. Reduction by prostacyclin of acetaminophen-induced toxicity in the mouse. Hepatology 1988; 8: 249-53.
33. Masaki N, Ohta Y, Shirataki H et al. Hepatocyte membrane stabilization by prostaglandin E1 and E2: favorable effects on rat liver injury. Gastroenterology 1992; 102: 572-6.
34. Sinclair SB, Greig PD, Blendis LM et al. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E. A preliminary report. J. Clin. Invest. 1989; 84: 1063-9.
35. Sheener P, Sinclair S, Greig P, Logan A, Blendis LM, Levy G. A randomized controlled trial of prostaglandin E2 in the treatment of fulminant hepatic failure. Hepatology 1992; 16: 88A.
36. O'Brien CB, Henzel BS, Naji A, Brass CA. Prostaglandin E1 infusion is effective in the late treatment of patients with acetaminophen induced acute hepatic failure referred for liver transplantation. Gastroenterology 1992; 102: A862.
37. Fernandez M, Garcia-Pagan JC, Casadevall M et al. Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. Gastroenterology 1996; 110: 1529-35.